2002-1997 Archive

September 9, 2002
diaDexus and Emory University Enter Cancer Research Collaboration Targeting Nox-1 Enzyme

September 4, 2002
diaDexus and the University of Michigan Enter Proteomics Collaboration to Identify Cancer Drug Targets and Biomarkers

April 17, 2002
diaDexus Collaborates With Mayo Medical Laboratories and Mayo Clinic To Expand Clinical Applications for Cardiovascular Risk Assessment Test

March 5, 2002
diaDexus Names Jacqueline Papkoff, Ph.D. Vice President of Discovery

February 19, 2002
Beyond Genomics and diaDexus Enter Research and License Agreement to Identify and Develop Cancer Biomarkers and Drug Targets

January 16, 2002
Compugen and diaDexus Announce Agreement for Identification of New Diagnostic Markers and Therapeutic Targets

December 6, 2001
diaDexus Grants License to Quest Diagnostics for Novel Genomics-Based Colorectal Cancer Diagnostic Test

November 21, 2001
diaDexus Grants License to Quest Diagnostics for Novel Genomics-Based Osteoporosis Diagnostic Test

August 9, 2001
diaDexus and Fujirebio announce collaboration for development and commercialization of novel cancer tests

June 19, 2001
diaDexus Appoints Two New Members to Its Board of Directors

May 23, 2001
diaDexus Announces Patent for Uterine Cancer Test

March 21, 2001
diaDexus Announces Issued U.S. Patent for Atherosclerosis Diagnostic Test

November 30, 2000
diaDexus Appoints New Research and Development Executivesg

November 20, 2000
diaDexus, Inc. Files For Initial Public Offering

October 23, 2000
diaDexus to use Agilent Technologies' DNA Microarrays to Further Cancer Research

October 18, 2000
diaDexus Develops Test for Novel, Independent Risk Factor

June 20, 2000
diaDexus Names Patrick Plewman as Chief Executive Officer

April 11, 2000
diaDexus Closes $102.5 Million Private PLAcement

September 2, 1997
SmithKline Beecham and Incyte Announce the Formation of diaDexus, a Joint Venture in Molecular Diagnostics